2‐arachidonyl glycerol activates platelets via conversion to arachidonic acid and not by direct activation of cannabinoid receptors - Keown, Oliver P.; Winterburn, Timothy J.; Wainwright, Cherry L.; Macrury, Sandra M.; Neilson, Ilene; Barrett, Fiona; Leslie, Stephen J.; Megson, Ian L. (British journal of clinical pharmacology, 2010)
Keywords: 2‐AG; Adolescent; Adult; Aged; AM251; antithrombotic; Arachidonic Acids - pharmacology; Arachidonic Acids - therapeutic use; Aspirin - pharmacology; Biological and medical sciences; Blood Platelets - chemistry; Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators - pharmacology; Cannabinoid Receptor Modulators - therapeutic use; Coronary Artery Disease - drug therapy; endocannabinoid system; Endocannabinoids; Glycerides - pharmacology; Glycerides - therapeutic use; Humans; Indoles - pharmacology; Male; Medical sciences; Middle Aged; Pharmacodynamics; Pharmacology. Drug treatments; Piperidines - pharmacology; Platelet Activation - drug effects; Platelet Aggregation - drug effects; Platelet Aggregation Inhibitors - pharmacology; platelets; Pyrazoles - pharmacology; rimonabant; Young Adult; CB1 cannabinoid receptor; Polyunsaturated fatty acid; Lipids; Arachidonic acid; Cannabinoid; Prokinetic agent; Conversion; antithrombotic; platelets; Platelet; n-6 fatty acid; Endogenous; Endocannabinoid; Rimonabant; AM251; Cannabinoid receptor; 2-AG; Antithrombotic agent; Unsaturated fatty acid; endocannabinoid system; Antagonist; Anorectic; 2-arachidonyl glycerol